Asis Shrestha

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Assistant Professor

UAMS

COM | Internal Med Hem-Onc

1 h-index 1 pubs 1 cited

Research Areas

Biomedical Subjects

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Asis Shrestha's research focuses on the immunogenicity and safety of influenza vaccines, particularly in older adults. His work includes a randomized Phase III trial comparing a quadrivalent high-dose inactivated influenza vaccine with a standard-dose vaccine in individuals aged 60 and above. Shrestha also investigates the effectiveness of high-dose influenza vaccines for preventing cardiovascular and respiratory events in those aged 65 and older through real-world pragmatic randomized clinical trials. Additionally, his research extends to multiple myeloma, examining the effect of Intravenous Immunoglobulin (IVIG) supplementation on infection-free survival in patients receiving BCMA-directed bispecific antibody therapy. His publications also address case definitions and guidelines for data collection and analysis related to immunization safety, including congenital anomalies, congenital microcephaly, and neonatal seizures.

Metrics

h-index: 1
Publications: 1
Citations: 1

Positions

Hospitalist 2020–present

Rochester General Hospital Internal Medicine ORCID
Assistant Professor publications 2026

University of Arkansas for Medical Sciences COM | Internal Med Hem-Onc Institutional directory

Selected Publications

Prognostic impact of lymphocyte kinetics and immune composition during bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Blood Cancer Journal DOI OpenAlex
Correction: Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal 1 citation DOI OpenAlex
The prognostic impact of lymphocyte counts and immune composition in bispecific antibody therapy in relapsed/refractory multiple myeloma (2026)

Research Square DOI OpenAlex
Real-world infectious complications and IVIG utilization after teclistamab in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Influence of genomic and clinical high-risk features on outcomes after BCMA-directed bispecific antibody therapy in relapsed/refractory multiple myeloma. (2026)

Journal of Clinical Oncology DOI OpenAlex
Clinical outcomes and risk factors of cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients (2026)

Blood Cancer Journal DOI OpenAlex
Integrating Gene Expression With Recurrent Mutations Improves Age‐Stratified Risk Prediction in Acute Myeloid Leukemia (2026)

eJHaem DOI OpenAlex
Abstract PS2-06-05: Comparing Cross-Toxicities and Efficacy of Everolimus and Alpelisib in Different Sequences in Metastatic Breast Cancer Patients (2026)

Clinical Cancer Research DOI OpenAlex
Prognostic Impact of European LeukemiaNet Genetic Risk Stratification System in Adult Patients With Acute Myeloid Leukemia (2026)

Aging and Cancer 1 citation DOI OpenAlex
Cytomegalovirus reactivation in teclistamab-treated multiple myeloma patients: Clinical outcomes and risk factors (2025)

Blood DOI OpenAlex
The efficacy of teclistamab in patients with multiple myeloma and secondary plasma cell leukemia (2025)

Blood Advances 5 citations DOI OpenAlex
Producing high quality cranial SRS plans with 4Pi planning technique in a commercial clinical solution (2025)

DOI OpenAlex
Case Report: Teclistamab in the treatment of idiopathic immune thrombocytopenia in patients with multiple myeloma (2025)

Frontiers in Hematology 2 citations DOI OpenAlex
Effect of Intravenous Immunoglobulin (IVIG) Supplementation on infection-free survival in recipients of BCMA-directed bispecific antibody therapy for multiple myeloma (2025)

Blood Cancer Journal 39 citations DOI OpenAlex
The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia (2024)

Blood 1 citation DOI OpenAlex